The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Clinical pharmacology of platelet cyclooxygenase inhibition.
Abstract
Nonsteroidal anti-inflammatory drugs and sulfinpyrazone compete dose-dependently with arachidonate for binding to platelet cyclooxygenase. Such a process closely follows systemic plasma drug concentrations and is reversible as a function of drug elimination. Peak inhibition and extent of its reversibility at 24 hr varies consistently with individual pharmacokinetic profile. Inhibition of platelet cyclooxygenase activity by these agents is associated with variable effects on prostaglandin (PG) synthesis in the gastric mucosa and the kidney. Aspirin acetylates platelet cyclooxygenase and permanently inhibits thromboxane (TX) A2 production in a dose-dependent fashion when single doses of 0.1 to 2.0 mg/kg are given. Acetylation of the enzyme by low-dose aspirin is cumulative on repeated dosing. The fractional dose of aspirin necessary to achieve a given level of acetylation by virtue of cumulative effects approximately equals the fractional daily platelet turnover. Serum TXB2 measurements obtained during long-term dosing with 0.11, 0.22, and 0.44 mg/kg aspirin in four healthy subjects could be fitted by a theoretical model assuming identical acetylation of platelet (irreversible) and megakaryocyte (reversible) cyclooxygenase. For a given dose within this range, both the rate at which cumulative acetylation occurs and its maximal extent largely depend upon the rate of platelet turnover. Continuous administration of low-dose aspirin (20 to 40 mg/day) has no statistically significant effect on urinary excretion of either 6-keto-PGF1 alpha or 2,3-dinor-6-keto-PGF1 alpha, i.e., indexes of renal and extrarenal PGI2 biosynthesis in vivo. Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, H. D., Davis, J. W., Archibald, D. G., Steinke, W. E., Smitherman, T. C., Doherty, J. E., Schnaper, H. W., LeWinter, M. M., Linares, E., Pouget, J. M., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090703 · Cited by 1,709
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 937
Self-citationFitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & Brash, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 665
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
Patrono, C., Ciabattoni, G., Pinca, E., Pugliese, F., Castrucci, G., De Salvo, A., Satta, M. A., & Peskar, B. A. (1980) · Thrombosis Research · doi:10.1016/0049-3848(80)90066-3 · Cited by 651
Self-citationDose-Related Kinetics of Aspirin: Presystemic Acetylation of Platelet Cyclooxygenase
Pedersen, A. K., & FitzGerald, G. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411083111902 · Cited by 558
Inhibition of platelet prostaglandin synthetase by oral aspirin.
Burch, J. W., Stanford, N., & Majerus, P. W. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108941 · Cited by 558
Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
FitzGerald, G. A., Smith, B., Pedersen, A. K., & Brash, A. R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404263101701 · Cited by 497
Weksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., Tack-Goldman, K., & Gay, W. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304073081402 · Cited by 448
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa
Whittle, B. J. R., Higgs, G. A., Eakins, K. E., Moncada, S., & Vane, J. R. (1980) · Nature · doi:10.1038/284271a0 · Cited by 392
Cited by
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,641
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000404 · Cited by 1,355
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Self-citationThe United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
Farrell, B., Godwin, J., Richards, S., & Warlow, C. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.12.1044 · Cited by 1,203
Secondary prevention of vascular disease by prolonged antiplatelet treatment
Antiplatelet Trialists' Collaboration (1988) · BMJ · doi:10.1136/bmj.296.6618.320 · Cited by 1,047
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Self-citationAspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Self-citationAspirin in Patients Undergoing Noncardiac Surgery
Devereaux, P. J., Mrkobrada, M., Sessler, D. I., Leslie, K., Alonso-Coello, P., Kurz, A., Villar, J. C., Sigamani, A., Biccard, B. M., Meyhoff, C. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401105 · Cited by 932
Berger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G., & Brown, D. L. (2006) · JAMA · doi:10.1001/jama.295.3.306 · Cited by 789
(1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251801 · Cited by 759
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Self-citationThe management of antithrombotic agents for patients undergoing GI endoscopy
Acosta, R. D., Abraham, N. S., Chandrasekhara, V., Chathadi, K. V., Early, D. S., Eloubeidi, M. A., Evans, J. A., Faulx, A. L., Fisher, D. A., Fonkalsrud, L., et al. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.09.035 · Cited by 719
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Self-citationThe Salt Collaborative Group (1991) · The Lancet · doi:10.1016/0140-6736(91)92233-r · Cited by 553
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Clinical Implications of Prostaglandin and Thromboxane A2Formation
Oates, J. A., FitzGerald, G. A., Branch, R. A., Jackson, E. K., Knapp, H. R., & Roberts, L. J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191206 · Cited by 444
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx334 · Cited by 409
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results
Uk-Tia Study Group (1988) · BMJ · doi:10.1136/bmj.296.6618.316 · Cited by 388
Clinical Implications of Prostaglandin and Thromboxane A2Formation
Oates, J. A., FitzGerald, G. A., Branch, R. A., Jackson, E. K., Knapp, H. R., & Roberts, L. J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809153191106 · Cited by 379
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis
Schafer, A. I. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04050.x · Cited by 367
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 2
Liu, J., Tang, T.-S., Tu, H., Nelson, O., Herndon, E., Huynh, D. P., Pulst, S. M., & Bezprozvanny, I. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0660-09.2009 · Cited by 299
Brideau, C., Kargman, S., Liu, S., Dallob, A. L., Ehrich, E. W., Rodger, I. W., & Chan, C. C. (1996) · Inflammation Research · doi:10.1007/bf02265118 · Cited by 279
A Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women
Manson, J. E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470040085027 · Cited by 272
Santilli, F., Rocca, B., De Cristofaro, R., Lattanzio, S., Pietrangelo, L., Habib, A., Pettinella, C., Recchiuti, A., Ferrante, E., Ciabattoni, G., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.047 · Cited by 265
Self-citationROCCA, B., SANTILLI, F., PITOCCO, D., MUCCI, L., PETRUCCI, G., VITACOLONNA, E., LATTANZIO, S., MATTOSCIO, D., ZACCARDI, F., LIANI, R., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04723.x · Cited by 256
Self-citationHermida, R. C., Ayala, D. E., Calvo, C., & López, J. E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.071 · Cited by 111
Aspirin resistance and diabetes mellitus
Ajjan, R., Storey, R. F., & Grant, P. J. (2008) · Diabetologia · doi:10.1007/s00125-007-0898-3 · Cited by 79
García Rodríguez, L. A., González-Pérez, A., Bueno, H., & Hwa, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016780 · Cited by 59
Metadata
- Authors
- Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., Davì, G., & Forni, L.
- Venue
- Circulation
- Published
- 1985-12
- Volume
- 72
- Issue
- 6
- Pages
- 1177-1184
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011861566
- Cited by
- 454
- References
- 25
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.